Out-licensing

Expanding access through proven portfolios

Through our B2B out‑licensing activities, we make high‑quality, affordable medicines available to partners worldwide. 

Explore out licensing opportunities

MoleculeDosage FormStrengthDossier AvailabilityATC Group
ABEMACICLIBTablet50 mg, 100 mg, 150 mgQ4 2027Antineoplastic and immunomodulating agents
ABIRATERONE ACETATEFilm-coated tablet500 mgLaunchedAntineoplastic and immunomodulating agents
ABIRATERONE ACETATEFilm-coated tablet1000 mgQ1 2027Antineoplastic and immunomodulating agents
AGOMELATINEFilm-coated tablet25 mgLaunchedAntidepressant
AGOMELATINEFilm-coated tablet50 mgQ1 2028Antineoplastic and immunomodulating agents
AMLODIPINETablet2.5 mg, 5 mg, 10 mgLaunchedCardiovascular system
AMLODIPINE BESILATE + CANDESARTAN CILEXETILTablet5 mg + 8 mg, 10 mg + 16 mgLaunchedCardiovascular system
AMLODIPINE BESILATE + CANDESARTAN CILEXETILTablet5 mg + 16 mgLaunchedCardiovascular system
AMLODIPINE BESILATE + CANDESARTAN CILEXETIL + INDAPAMIDETablet5 mg+8 mg+2.5 mg, 5 mg+16 mg+2.5 mg, 10 mg+16 mg+2.5 mgFiled in EUCardiovascular system
AMLODIPINE BESILATE + INDAPAMIDE + PERINDOPRIL ERBUMINETablet5 mg + 1.25 mg + 4 mg, 10 mg + 1.25 mg + 4 mg, 5 mg + 2.5 mg + 8 mg, 10 mg + 2.5 mg + 8 mgLaunchedCardiovascular system
AMLODIPINE BESILATE + PERINDOPRIL ERBUMINETablet5 mg + 4 mg, 10 mg + 4 mg, 5 mg + 8 mg, 10 mg + 8 mgLaunchedCardiovascular system
APALUTAMIDETablet60 mgQ3 2029Antineoplastic and immunomodulating agents
APIXABANFilm-coated tablet2.5 mg, 5 mgEU registeredBlood and blood forming organs
APREMILASTFilm-coated tablet10 mg, 20 mg, 30 mgEU registeredDermatological drugs
ARTICAINE + EPINEPHRINESolution for injection40 mg/5 mcg, 40 mg/10 mcgQ3 2027Nervous system
ATOMOXETINECapsule, hard10; 18; 25; 40; 60; 80; 100 mgLaunchedNervous system
ATORVASTATIN + EZETIMIBEFilm-coated tablet10mg + 10mg; 20mg + 10mg; 40mg + 10mg; 80mg + 10mgQ4 2026Cardiovascular system
BEMPEDOIC ACIDTablet180 mgQ2 2027Cardiovascular system
BEMPEDOIC ACID + EZETIMIBETablet180 mg+10 mgQ1 2028-
BENZYDAMINEOral spray0.15%, 0.30%Q2 2027Respiratory
BISOPROLOLOral solution0.5 mg/mlFiled in UKCardiovascular system
BISOPROLOL + EMPAGLIFLOZINTablet1.25 mg/10 mg, 2.5 mg/10 mg, 5 mg/10 mg, 10 mg/10 mgQ2 2029Cardiovascular system
CANDESARTAN + LERCANIDIPINTablet8 mg/5 mg, 16 mg/10 mg, 16 mg/20 mgQ1 2028-
DAPAGLIFLOZINFilm-coated tablet5 mg, 10 mgFiled in EUAlimentary tract and metabolism
DAPAGLIFLOZIN + METFORMINFilm-coated tablet5 mg + 850 mg, 5 mg + 1000 mgQ1 2026Alimentary tract and metabolism
DASATINIB (pH resistant)Film-coated tablet15.8 mg, 35.5 mg, 55.3 mg, 63.2 mg, 79 mg, 110.6 mgLaunchedAntineoplastic and immunomodulating agents
DEFERASIROXFilm-coated tablet90 mg, 180 mg, 360 mgLaunchedVarious ATC structures
DEXAMETHASONESolution for injection4 mg/mlIn developmentVarious ATC structures
DEXIBUPROFENFilm-coated tablet200 mg, 300 mg, 400 mgIn developmentNervous system
DOLUTEGRAVIRFilm-coated tablet50 mgDossier readyAnti-infectives for systemic use
DOLUTEGRAVIR + LAMIVUDINEFilm-coated tablet50 mg + 300 mgQ2 2027Anti-infectives for systemic use
EDOXABANFilm-coated tablet15 mg, 30 mg, 60 mgLaunchedBlood and blood forming organs
EMPAGLIFLOZINFilm-coated tablet10 mg, 25 mgQ3 2026Alimentary tract and metabolism
EMPAGLIFLOZIN + METFORMINFilm-coated tablet5mg + 850mg, 12,5mg + 850 mg, 5mg + 1000mg, 12,5mg + 1000 mgQ4 2026Alimentary tract and metabolism
EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDEFilm-coated tablet200 mg + 25 mg + 25 mg, 200 mg + 27.5 mg + 28 mgFiled in EUAntivirotic
EMTRICITABINE + TENOFOVIR ALAFENAMIDEFilm-coated tablet200 mg + 10 mg, 200 mg + 25 mgEU registeredAntivirotic
ESOMEPRAZOLE + NAPROXENTablet500mg + 20mgQ3 2027Musculoskeletal system
ETORICOXIBFilm-coated tablet30 mg, 60 mg, 90 mg, 120 mgLaunchedMusculoskeletal system
FAMOTIDINEFilm-coated tablet10mg, 20 mg, 40 mgIn developmentAlimentary tract and metabolism
FINGOLIMODCapsule, hard0.5 mgLaunchedMultiple sclerosis
HYDROCHLOROTHIAZIDE+ LOSARTAN POTASSIUMFilm-coated tablet12.5 mg + 50 mg, 12.5 mg + 100 mg, 25 mg + 100 mgLaunchedCardiovascular system
IBANDRONATE SODIUM MONOHYDRATEFilm-coated tablet150 mgLaunchedMusculoskeletal system
IBUPROFENFilm-coated tablet200 mg, 400 mg, 600 mg, 800 mgLaunchedNervous system
IBUPROFENOral suspension100 mg/5 ml (2%), 200 mg/5 ml (4%)Dossier readyNervous system
IBUPROFEN IR + SR OTCTablet400 IR + SREU registeredNervous system
IBUPROFEN LYSINATEFilm-coated tablet400 MGEU registeredNervous system
LACOSAMIDEFilm-coated tablet50 mg, 100 mg 150 mg, 200 mgLaunchedNervous system
LEVETIRACETAMFilm-coated tablet250 mg, 500 mg, 750 mg, 1000 mgLaunchedNervous system
LINAGLIPTINFilm-coated tablet5 mgEU registeredAlimentary tract and metabolism
LORAZEPAMTablet0.5 mgLaunchedNervous system
MELATONINTablet3mg, 5mgQ2 2027Nervous system
METAMIZOLE SODIUMFilm-coated tablet500 mgLaunchedNervous system
METAMIZOLE SODIUMInjection500 mg/ml (2 ml)LaunchedNervous system
METFORMIN + SITAGLIPTINFilm-coated tablet1000 mg/50 mg, 850 mg/50 mgLaunchedAlimentary tract and metabolism
METFORMIN HYDROCHLORIDEFilm-coated tablet500 mg, 850 mg, 1000 mgLaunchedAlimentary tract and metabolism
NOREPINEPHRINEInjection1 mg / 1 mlEU registeredCardiovascular system
OMEPRAZOLE + ANTACIDUMCapsule20 mgLaunchedAlimentary tract and metabolism
PARACETAMOLOral suspension40 mg/mlFiled in EUNervous system
PERINDOPRIL ARGININEFilm-coated tablet2.5 mg, 5 mg, 10 mgLaunchedCardiovascular system
PRASUGREL HYDROCHLORIDEFilm-coated tablet10 mgEU registeredBlood and blood forming organs
RILMENIDINETablet1 mgLaunchedCardiovascular system
RIVAROXABANFilm-coated tablet2.5 mg, 10 mg, 15 mg, 20 mgLaunchedBlood and blood forming organs
RIVAROXABANCapsule, hard10 mg, 15 mg, 20 mgLaunchedBlood and blood forming organs
RIVAROXABAN suspensionOral suspension5 mg/mlLaunchedBlood and blood forming organs
ROXADUSTATFilm-coated tablet20 mg, 50 mg, 70 mg, 100 mg, 150 mgQ2 2029Blood and blood forming organs
SACUBITRIL + VALSARTANFilm-coated tablet24 mg + 26 mg, 49 mg + 51 mg, 97 mg + 103 mgQ2 2026Cardiovascular system
SERTRALINEFilm-coated tablet25 mgQ2 2026Nervous system
SERTRALINEFilm-coated tablet50 mg, 100 mgQ2 2026Nervous system
SITAGLIPTIN PHOSPHATEFilm-coated tablet25 mg, 50 mg, 100 mgLaunchedAlimentary tract and metabolism
SOLIFENACIN SUCCINATEFilm-coated tablet5 mg, 10 mgLaunchedGenitourinary system and reproductive hormones
TAMSULOSIN HYDROCHLORIDEModified-release capsule, hard0.4 mgLaunchedGenitourinary system and reproductive hormones
TICAGRELORFilm-coated tablet60 mg, 90 mgLaunchedBlood and blood forming organs
TORASEMIDETablet2.5 mg, 10 mg, 15 mg, 20 mgLaunchedCardiovascular system
URSODEOXYCHOLIC ACIDFilm-coated tablet250 mg, 500 mgQ4 2027Alimentary tract and metabolism
VARDENAFIL HYDROCHLORIDE TRIHYDRATEFilm-coated tablet5 mg, 10 mg, 20 mgLaunchedGenitourinary system and reproductive hormones
VILDAGLIPTINTablet50 mgLaunchedAlimentary tract and metabolism
VORTIOXETINEFilm-coated tablet5 mg, 10 mg, 15 mg, 20 mgFiled in EUNervous system

DISCLAIMER:

Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83and any other limitation imposed to Zentiva by contracts with 3rd parties . This catalogue shall not constitute an offer for the sale of products and processes for the territories where an offer for sale or sale is not permissible by law orby contracts between Zentiva and 3rd parties. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

*4B Zone stability can be fulfilled upon request if not available at the moment

""

Partner with us

At Zentiva, our growth is powered by strong, trusted partnerships. Together, we’re building the foundation for a more sustainable healthcare system, making a lasting, positive impact on  the availability of medicines and on public health across Europe and beyond.

GET IN TOUCH